Company / R&D Expense
GRAIL, Inc. R&D Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$195.8M
FY2025
5-year range
$195.8M / $338.7M
FY2022-FY2025
Trend
-39.3%
vs FY2024
Sector context
#37 of 110
Health Care
What the data says
At $196M, GRAIL, Inc.'s r&d expense ranks #37 of 110 in the Health Care sector. Declined from $339M to $196M over the past 2 years.
Based on SEC 10-K filings.
$196M in FY2025 with a 3-year CAGR of -15.9%.
Declined from $339M to $196M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -15.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#37 of 110 in Health CareTop 34% of 110This company $195.8M Sector average $298.2M
▼
-34.3% below sector average
Key checks
Key Insights
- 3-year CAGR of -15.9%, indicating a declining trend.
- In FY2025, r&d expense decreased 39.3% year-over-year.
- Ranks #37 out of 110 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $195.8M | -39.3% |
| FY2024 | $322.4M | -4.8% |
| FY2023 | $338.7M | +2.8% |
| FY2022 | $329.6M | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026